All In MedTech

FDA Clearance Tracker · P960007-S017

TRANSCYTE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 28, 2004 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 28, 2004

Approved

Time to decision

676 days

Received Aug 22, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P960007-S017
Device name
TRANSCYTE
Applicant location
San Diego, CA
Received
Aug 22, 2002
Decided
Jun 28, 2004
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P960007

Device type

Device class
Class III

Every decision under product code MGR

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE TERMINATION OF THE POST-APPROVAL STUDY PROTOCOL ENTITLE: "A RANDOMIZED, CONTROLLED WITHIN-PATIENT-PAIRED STUDY TO COMPARE THE EFFECTIVENESS OF TRANSCYTE AND BIOBRANE IN THE TREATMENT OF MID-DERMAL TO INDETERMINATE DEPTH BURN WOUNDS."

Source documents

Other decisions for Shire Regenerative Medicine

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.